Extracellular adenosine enhances the ability of PMNs to kill *Streptococcus pneumoniae* by inhibiting IL-10 production

Nalat Siwapornchai^{*,†}, James N. Lee^{*,†}, Essi Y. I. Tchalla[‡], Manmeet Bhalla[‡], Jun Hui Yeoh[‡], Sara E. Roggensack[†], John M. Leong[†] and Elsa N. Bou Ghanem[‡]

Author affiliations: [†]Department of Molecular Biology and Microbiology at Tufts University School of Medicine, Boston, MA 02111 USA

[‡]Department of Microbiology and Immunology, University at Buffalo School of Medicine, Buffalo, NY 14203, USA

*These authors contributed equally to this work

Summary Sentence: Extracellular adenosine produced by CD73 promotes the ability of PMNs to kill *Streptococcus pneumoniae* by blunting IL-10 production

Running Title: PMN anti-bacterial phenotype requires CD73

Corresponding author information: Elsa N. Bou Ghanem, 955 Main Street, Buffalo, NY, 14203. Telephone: 716-829-2422. Email: elsaboug@buffalo.edu

Key Words: Neutrophil phenotype, CD73, anti-microbial, pneumonia, reactive oxygen species

24 **Abbreviations**

25 CFU: Colony Forming Units

26 CT: Cycle Thresh-hold

27 EAD: Extracellular Adenosine

28 I.P: Intra Peritoneal

29 I.T: Intra Tracheal

30 MFI (Mean Fluorescent Intensity)

31 MOI: Multiplicity of Infection

32 MPO: Myeloperoxidase

33 NE: Neutrophil Elastase

34 OPH: Opsonophagocytic

35 PLY: Pneumolysin

36 PMA: Phorbol 12-myristate 13-acetate

37 PMNs: Polymorphonuclear Leukocytes

38 Pneumococcus: *Streptococcus pneumoniae*

39 ROS: Reactive Oxygen Species

40 SodA: Superoxide Dismutase

41 WT: Wild Type

42

43

44

45

46

Abstract

PMNs are crucial for initial control of *Streptococcus pneumoniae* (pneumococcus) lung infection; however, as the infection progresses their persistence in the lungs becomes detrimental. Here we explored why the anti-microbial efficacy of PMNs declines over the course of infection. We found that the progressive inability of PMNs to control infection correlated with phenotypic differences characterized by a decrease in CD73 expression, an enzyme required for production of extracellular adenosine (EAD). EAD production by CD73 was crucial for the ability of both murine and human PMNs to kill *S. pneumoniae*. In exploring the mechanisms by which CD73 controlled PMN function, we found that CD73 mediated its anti-microbial activity by inhibiting IL-10 production. PMNs from wild type mice did not increase IL-10 production in response to *S. pneumoniae*, however, CD73^{-/-} PMNs up-regulated IL-10 production upon pneumococcal infection *in vitro* and during lung challenge. IL-10 inhibited the ability of wild type PMNs to kill pneumococci. Conversely, blocking IL-10 boosted the bactericidal activity of CD73^{-/-} PMNs as well as host resistance of CD73^{-/-} mice to pneumococcal pneumonia. CD73/IL-10 did not affect apoptosis, bacterial uptake and intracellular killing or production of anti-microbial Neutrophil Elastase and Myeloperoxidase. Rather, inhibition of IL-10 production by CD73 was important for optimal ROS production by PMNs. ROS contributed to PMN anti-microbial function as their removal or detoxification impaired the ability of PMNs to efficiently kill *S. pneumoniae*. This study demonstrates that CD73 controls PMN anti-microbial phenotype during *S. pneumoniae* infection.

1. Introduction

Neutrophils, also known as polymorphonuclear leukocytes or PMNs, play a major role in host defense against *S. pneumoniae* lung infection (1, 2). PMNs are required to control bacterial burden early in the infectious process. In mouse models, early PMN recruitment into the lungs within the first 12 hours following pneumococcal pulmonary infection coincided with a decrease in bacterial numbers and immunodepletion of PMNs prior to infection resulted in host lethality (3). *Ex vivo*, PMNs are thought to kill *S. pneumoniae* by engulfing the bacteria and producing serine proteases including cathepsin G (CG) and neutrophil elastase (NE) (4), which also play a role in controlling bacterial numbers in murine models of pneumonia (5). Interestingly, later during infection, PMN persistence in the lungs promotes disease (3, 6, 7). In fact, we previously found that depletion of PMNs 18 hours after pneumococcal lung infection results in reduced bacterial numbers and enhanced mouse survival (3). These findings demonstrate that while PMNs are required at the start of infection, their persistence is detrimental for host survival. This also suggested that the antibacterial function of these innate immune cells and their ability to clear pneumococci is altered during the course of infection (3). However, the mechanisms of this alteration in PMN phenotype remain unexplored.

A major regulator of host resistance to pneumococcal infection is extracellular adenosine (EAD) (3). Upon damage due to a variety of insults including infection, ATP is thought to leak from damaged cells into the

extracellular space and is converted into EAD by the sequential action of two exonucleosidases, CD39 and CD73 (8). EAD can then signal via four known receptors, i.e. A1, A2A, A2B and A3 (9). Several drugs targeting this pathway are in clinical studies (9), making it an attractive avenue for modulating immune responses during infection. We previously found that blocking EAD production by CD73 dramatically increases bacterial numbers in organs and results in host lethality upon *S. pneumoniae* lung infection in mice (3). EAD production by CD73 regulates PMN recruitment to the lungs and potentially boosts PMN function (3).

IL-10 is an anti-inflammatory cytokine associated with impaired control of pneumococcal pneumonia (10, 11). In mouse models, IL-10 levels increase in the lungs within 12 hours following pneumococcal challenge (10). Intranasal administration of IL-10 at the time of bacterial challenge results in decreased host survival and increased bacterial numbers in the lungs and blood, while blocking IL-10 enhances bacterial clearance and boosts host survival (10). Interestingly, while IL-10^{-/-} mice have reduced lung and systemic bacterial loads, these mice suffer increased mortality due to excessive pulmonary inflammation (12). IL-10 can be produced by many types of immune cells and it is now appreciated that murine PMNs produce this anti-inflammatory cytokine during infections (13-16). PMNs are a significant source of IL-10 in sepsis models (17) and stimulation with several bacterial pathogens, including *Escherichia coli*, *Shigella flexneri* and mycobacterial BCG, triggers IL-10 production by PMNs both *in vitro* and *in vivo* within 8 hours of infection (16). Parasitic infections such as *Leishmania major* (14) and *Trypanosoma cruzi* (15) also induce IL-10-producing PMNs during mouse

infection. IL-10 production by PMNs may reduce their microbicidal capacity, as *in vitro* treatment of PMNs with IL-10 impairs their ability to phagocytose *Staphylococcus aureus*, *Candida albicans* and *E. coli* and blunts superoxide production (18, 19). Further, in a *S. aureus* burn infection model, a subset of IL-10 producing PMNs is associated with impaired host resistance to infection (13). It is not currently known if *S. pneumoniae* infection triggers IL-10 production by PMNs.

In this study, we explored the involvement of CD73 in the diminished anti-microbial efficacy of PMNs during the course of pneumococcal pneumonia. We found that during the course of lung infection, CD73 expression on PMNs decreased. Notably, this change in CD73 expression coincided with an increase in IL-10-producing PMNs. CD73 suppressed IL-10 production by PMNs during infection and was required for the ability of these cells to kill *S. pneumoniae*. This study identifies a role for CD73 in maintaining the antimicrobial phenotype of PMNs and elucidates the mechanisms by which CD73 regulates PMN anti-microbial function and host resistance against *S. pneumoniae*.

2. Materials and Methods

2.1 Mice

All experiments were conducted in accordance with Institutional Animal Care and Use Committee (IACUC) guidelines. Wild type (WT) C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME). CD73^{-/-} mice on C57BL/6 background (8) were purchased from Jackson Laboratories and bred at

a specific-pathogen free facility at Tufts University and The University at Buffalo.

Female 8-12-week-old mice were used in all experiments.

2.2 Bacteria

Wild type *S. pneumoniae* TIGR4 AC316 strain (serotype 4) and pneumolysin-deletion mutant (Δ PLY) *S. pneumoniae* (20) were kind gifts from Andrew Camilli.

The superoxide dismutase in-frame deletion mutant (Δ sodA) strain was constructed via allelic exchange using linear pieces of DNA amplified by PCR and the co-transformation approach previously outlined (21). Primers SP_0766_F1 and SP_0766_R1 (table 1) were used to generate a linear piece of DNA with homologous sequences in the pneumococcal genome upstream of *sodA*, and primers SP_0766_F2 and SP_0766_R2 (table 1) amplified the region downstream of *sodA*. These primers were designed with overlapping sequences, such that when assembled using NEBuilder followed by a final PCR amplification with the F1 and R2 primers (table 1), the entirety of the *sodA* sequence is deleted except for the start and stop codons. The Δ SP_1051::cat sequence was amplified from an existing Δ SP_1051::cat strain in the AC316 background (21) using primers OS38 and OS39 (table 1). The two pieces of linear DNA were transformed simultaneously into AC316 in a molar ratio of unmarked to marked approximately 20:1. In cells that took up both pieces of linear DNA and recombined them into the genome, *sodA* was deleted from the genome while neutral gene SP_1051 was replaced with a chloramphenicol resistance cassette. Chloramphenicol-resistant transformants were screened for the gene deletion via

colony PCR using primers SP_0766_ColonyPCRF and SP_0766_ColonyPCRR (table 1). Double-positive clones were grown and saved in THY/glycerol for further verification. PCR amplification of both the Δ SP_1051::cat and Δ sodA regions were performed using template gDNA extracted from a double-positive clone. Amplified DNA was run on agarose gels and imaged under UV-illumination. All bacteria were grown at 37°C in 5% CO₂ in Todd-Hewitt broth supplemented with 0.5% yeast extract and oxyrase until culture reached mid-exponential phase. Bacterial aliquots were frozen at -80°C in the growth media with 20% (v/v) glycerol. Prior to use, aliquots were thawed on ice, washed and suspended in PBS to obtain the appropriate concentration. The inoculums were then confirmed by serial dilution and dribble plating on Tryptic Soy Agar plates supplemented with 5% sheep blood agar.

2.3 Isolation of PMNs

Bone marrow cells were harvested from femurs and tibias of uninfected mice, flushed with RPMI 1640 supplemented with 10% FBS and 2 mM EDTA, and resuspended in PBS. Neutrophils were then separated from the rest of the bone marrow cells through density gradient centrifugation, using Histopaque 1119 and Histopaque 1077 as previously described (22). The isolated neutrophils were resuspended in Hanks' Balanced Salt Solution (HBSS)/0.1% gelatin without Ca²⁺ and Mg²⁺, and used in subsequent assays. The purity of neutrophils was also measured by flow cytometry using APC-conjugated anti-Ly6G and 85-90% of enriched cells were Ly6G+.

185

186 *2.4 Opsonophagocytic killing assay*

187 The ability of PMNs to kill pneumococci was assessed *ex vivo* through an
 188 Opsonophagocytic (OPH) killing assay as previously described (3, 23). Briefly,
 189 100µl reactions in HBSS/0.1% gelatin consisted of 1×10^5 PMNs incubated with
 190 1×10^3 bacteria grown to mid log phase and pre-opsonized with 3% mouse sera.
 191 The reactions were incubated rotating for 45 minutes at 37°C. Where indicated,
 192 PMNs were incubated with adenosine (100µM), rIL-10 (50ng/mL), anti-IL10
 193 (1ug/mL JES5-2A5) or isotype control (1ug/mL), 1x protease inhibitor cocktail,
 194 the CD37 inhibitor (100µM α, β methylene ADP), the CD39 inhibitor (100µM
 195 POM-1), the ROS inhibitor Diphenyleneiodonium (DPI, 10µM) or the anti-oxidants
 196 EUK134 (25µM) or Ascorbic acid (100µM) for 30 minutes prior to adding pre-
 197 opsonized bacteria. IL-10 reagents were purchased from Biolegend and the
 198 inhibitors from Sigma. HBSS with 3% sera was added to PMNs without treatment
 199 as the control. Percent killing was determined by dribble plating on blood agar
 200 plates and calculated in comparison to no PMN control under the exact same
 201 conditions (+/- treatments).

202

203 *2.5 IL-10 Enzyme-Linked Immunosorbent Assay (ELISA)*

204 1×10^6 Bone marrow PMNs were incubated with HBSS/0.1% gelatin or adenosine
 205 for 30 minutes, followed by 45 minutes infection at 37°C with pre-opsonized *S.*
 206 *pneumoniae* TIGR4 at a MOI of 2 or mock treated with HBSS and sera only
 207 (uninfected). The reactions were spun down and the supernatants were obtained

to measure IL-10 production using Mouse IL-10 ELISA kit (eBioscience)

according to manufacturer's instructions.

2.6 ROS Assay

Following isolation from the bone marrow, PMNs were re-suspended in HBSS (Ca²⁺ and Mg²⁺ free) and acclimated at room temperature for one hour. The cells were then spun down and re-suspended in KRP buffer (Phosphate buffered saline with 5mM glucose, 1mM CaCl₂ and 1mM MgSO₄) and equilibrated at room temperature for 30 minutes. The cells were then seeded in 96-well white LUMITRACTM plates (Greiner Bio-One) at 5x10⁵ PMNs per well, treated with adenosine, anti-IL-10 or rIL-10 for 30 minutes at 37° C. For detection of extracellular ROS, 50µM Isoluminol (Sigma) plus 10U/ml HRP (Sigma) were added, while for detection of intracellular ROS, 50µM Luminol (Sigma) was added to the wells as previously described (24-27). The cells were infected with pre-opsonized *S. pneumoniae* TIGR4 at a MOI of 2 or mock treated with buffer containing 3% mouse sera (uninfected). PMNs treated with 100 nM Phorbol 12-myristate 13-acetate (PMA) (Sigma) were used as a positive control. Luminescence was immediately read (following infection) over a period of one hour at 37° C in a pre-warmed Biotek Plate reader. Wells containing buffer and Isoluminol plus HRP or Luminol alone were used as blanks.

2.7 Animal infections and scoring

Mice were lightly anesthetized with isoflurane and challenged intra-tracheally (i.t.)

with 5×10^5 colony-forming units (CFU) of WT *S. pneumoniae* TIGR4 strain by instilling 50 μ l of bacteria directly into the trachea with the tongue pulled out to facilitate delivery of bacteria directly into the lungs (3). Following the infection, mice were monitored daily for weight loss and blindly scored for signs of sickness including weight loss, activity level, posture and breathing, scored as healthy [0] to severely sick [21] as previously described (28). The lung and brain were harvested and homogenized in sterile PBS. Blood was collected to follow bacteremia. Each sample was diluted in sterile PBS and dribble plated on blood agar plates to enumerate bacterial numbers.

2.8 Isolation of cells from the lungs and flow cytometry

Mice were perfused with 10ml PBS, the lungs removed, washed in PBS, and minced into small pieces. The lungs were then digested for 1 hour with RPMI 1640 supplemented with 10% FBS, 1 mg/ml Type II collagenase (Worthington), and 50 U/ml Deoxyribonuclease I (Worthington) at 37° C/ 5% CO₂. Single-cell suspensions were obtained by mashing the digested lungs, and the red blood cells were removed by treatment with a hypotonic lysis buffer (Lonza). Cells were analyzed using flow cytometry. Intracellular cytokine staining (ICS) was performed using the Cytofix/Cytoperm kit (BD Biosciences). GolgiPlug was added to the digestion media and following red blood cell lysis, the cells were incubated with RPMI 1640 supplemented with 10% FBS and Golgi Plug for 3 more hours at 37° C/ 5% CO₂. Cells were surface stained with anti-mouse CD45 (clone 30-F11, eBioscience), Ly6G (clone 1A8, BD Biosciences) and CD73

(Clone TY/11.8, eBioscience). For intracellular staining, cells were permeabilized and stained with IL-10 (clone JES5-16E3, eBioscience) or isotype control (Rat IgG2b K Isotype Control, Biolegend). Fluorescence intensities were measured on a FACSCalibur and at least 25,000 events for lung tissue were analyzed using FlowJo.

2.9 Adoptive transfer of PMNs

Bone marrow PMNs were isolated from uninfected mice using density gradient centrifugation as described above and resuspended in PBS. Mice either received 2.5×10^6 cells via intraperitoneal (i.p.) injection as previously described (29) or mock-treated (PBS). One hour post-transfer, mice were challenged i.t. with 5×10^5 CFU of *S. pneumoniae*. Mice were euthanized at 24 hours post infection, and the lungs, brain, and blood were collected and plated on blood agar plates for CFU. The presence of transferred PMNs in the circulation of recipient mice was confirmed by flowcytometry (Fig S1).

2.10 Blocking IL-10 in vivo

Mice were treated with 0.1mg/mouse of IL-10 blocking antibody (JES52A5, Biolegend) or the isotype control (Rat IgG1 K Isotype Control, Biolegend) through i.p. injection. After 2 hours, mice were then challenged i.t. with 5×10^5 CFU of *S. pneumoniae*. The lungs and blood were collected two days post-infection to determine bacterial burden.

2.11 Assays with human PMNs

Young (23-38 years old), male and female healthy human volunteers were recruited in accordance with The University at Buffalo Human Investigation Review Board (IRB) and signed informed consent forms. Individuals taking medication, reporting symptoms of infection within the last 2 weeks or that were pregnant were excluded from the study. Whole blood was obtained using acid citrate/dextrose as an anti-coagulant. PMNs were isolated using a 2% gelatin sedimentation technique as previously described (30) which allows for isolation of active PMNs with ~90% purity. 5×10^5 PMNs were treated with the selective and competitive inhibitor of CD73, α, β methylene ADP (1 or $10 \mu\text{M}$) or DMSO vehicle control for 30 minutes at 37°C . The PMNs were then infected with 10^3 CFU *S. pneumoniae* pre-opsonized in 10% (v/v) baby rabbit serum (Pel-Freeze) for 45 minutes at 37°C with rotation. Samples were then placed on ice to stop the process of opsonophagocytosis followed by serial dilution and plating on blood agar plates to enumerate viable CFU. The percentage of bacterial killing was calculated relative to no PMN controls incubated under the same treatment conditions.

2.12 mRNA measurement

RNA was extracted from 2×10^6 human PMNs using the RNeasy Mini Kit (Qiagen) as per manufacturer's protocol. TURBO DNA-free kit (Invitrogen) was used to digest DNA from the RNA samples prior conversion into cDNA. RNA concentration and 260/280 ratio were determined using Nano-drop (Thermo

Fischer Scientific). For each sample, 500ng of RNA was converted into cDNA using SuperScript VILO™ cDNA synthesis kit (Life Technologies) according to the manufacturer's protocol. RT-PCR was performed using CFX96 Touch™ Real-Time PCR Detection System from Bio-Rad and CT (cycle thresh-hold) values were determined using the following TaqMan probes from Life Technologies (Thermo Fischer Scientific): GAPDH (human Hs99999905_m1) and IL-10 (human Hs00961622_m1). Each sample was run in duplicates. Data were analyzed by the comparative threshold cycle ($2^{-\Delta CT}$) method, normalizing the CT values obtained for IL-10 expression to those for GAPDH of the same sample. For comparison of IL-10 levels upon infection, relative quantity of transcripts (RQ) values were calculated by the $\Delta\Delta CT$ method by using the formula $RQ = 2^{-(\Delta\Delta CT)}$ (31). The $\Delta\Delta CT$ values were obtained by subtracting ΔCT value of the infected (test) from that of the uninfected control.

2.13 Statistics

All statistical analysis was performed using Prism7 (Graph Pad). CFU data were log-transformed to normalize distribution. For all graphs, the mean values +/- SD are shown. Significant differences were determined by 2-way ANOVA followed by Sidak's multiple comparisons test or Student's t-test where p values less than 0.05 were considered significant (as indicated by asterisks). Pearson test was used to determine correlation.

Online Supplemental Material

Adenosine measurement

Blood was collected from mice by venipuncture in microtainer tubes. The tubes were centrifuged at 9000rpm for 2 minutes and the sera obtained. Adenosine level in the sera was measured using the Adenosine Assay Fluorometric Kit (BioVision) as per manufacturer's instructions.

Bacterial uptake and intracellular killing assay

To determine uptake/phagocytosis and intracellular killing by PMNs, we performed a gentamicin-protection assay. Isolated PMNs from uninfected mice were incubated with pre-opsonized wild type or Δ PLY *S. pneumoniae* (MOI=2) for 10 minutes at 37°C. Gentamycin (100ug/ml) was then added for 40 minutes to kill extracellular bacteria. The reactions were washed three times with HBSS and resuspended in 100ul HBSS/0.1% gelatin. To measure initial bacterial uptake, the reactions were diluted and plated on blood agar plates and the percentage of the input inoculum that was engulfed was calculated. To determine intracellular killing, the reactions were returned to 37°C and incubated for 30 minutes and 90 minutes. The reactions were diluted and plated on blood agar plates and the percentage of the engulfed inoculum (at 10 minutes) that was killed was then calculated.

Myeloperoxidase (MPO) levels, Neutrophil Elastase and Cathepsin G activity assays

1x10⁶ Bone marrow PMNs were treated with adenosine, anti-IL-10 or rIL-10 or mock treated with HBSS/0.1% gelatin for 30 minutes at 37° C. The PMNs were then infected with pre-opsonized *S. pneumoniae* TIGR4 at a MOI of 2 or mock treated with buffer containing 3% mouse sera (uninfected) for 45 minutes at 37° C. The reactions were spun down and the supernatants were used to measure neutrophil elastase and cathepsin G activities as well as MPO levels with the Neutrophil Elastase Activity Assay Kit Fluorometric (Abcam), the Cathepsin G Activity Assay Kit (Abcam) and MPO ELISA (Invitrogen) respectively (30). The cells were lysed with lysis buffer containing 1% Triton-X, 50mM Tris, 0.1% SDS, 0.5% sodium deoxycholate and 150mM NaCl. MPO levels in the pellets were also measured by ELISA.

Apoptosis Assay

PMNs were pre-treated with buffer or incubated with anti-IL-10 or rIL-10 for 30 minutes at 37° C then infected with pre-opsonized *S. pneumoniae* TIGR4 at a MOI of 2 or mock treated with buffer containing 3% mouse sera (uninfected) for 45 minutes at 37° C. The percentage of apoptotic cells were then determined by flow cytometry using the FITC Annexin V apoptosis detection kit with PI (BioLegend) following manufacturer's instructions.

Tracking of transferred PMNs

Bone marrow PMNs were isolated from uninfected CD73^{-/-} or wildtype mice using density gradient centrifugation and then labeled with CellTracker Green (CMFDA

(5-Chloromethylfluorescein Diacetate) and CellTracker Orange (CMTMR (5-(and-6)-4-Chloromethyl Benzoyl Amino Tetramethylrhodamine) respectively as previously described (22). CD73^{-/-} mice were then injected with a 1:1 ratio of PMNs from each strain (1x10⁶ cells) via intraperitoneal (i.p.) injection. Three hours post transfer, recipient mice were euthanized, blood collected and the presence of transferred cells assessed by flow cytometry.

3. Results

3.1 CD73 expression on PMNs decreases over the course of infection

We previously found that PMNs are required for protection at the beginning of *S. pneumoniae* lung infection (3), but are detrimental at later times. To test if there was a correlation between PMN numbers in the lungs and bacterial burden, we infected young C57BL/6 mice intra-tracheally (i.t.) with 5x10⁵ colony-forming units (CFU) of *S. pneumoniae* TIGR4 strain. We then monitored the bacterial burden and pulmonary influx of PMNs and performed correlation analysis between PMN number and lung CFU for 0-12 hours vs. 18-72 hours following infection. We found that PMN influx into the lungs strongly correlated with a decrease in bacterial burden for the first 12 hours following infection (Fig 1A left panel, R-squared =0.71, *p*=0.0001). However, there was no correlation between PMN presence in the lungs and bacterial numbers for the remainder of the infection (Fig 1A right panel) suggesting that PMNs are no longer able to control the infection.

To determine if this was associated with a difference in the phenotype of pulmonary PMNs over time, we monitored the expression of the EAD-producing enzyme CD73 on PMNs in the lungs following challenge. We found that in the first 18 hours of infection, the majority (~75-80%) of PMNs in the lungs expressed CD73 (Fig. 1B). However, both the percentage of PMNs expressing CD73 and the amount (measured by the mean fluorescent intensity or MFI) of CD73 expressed on PMNs in the lungs significantly dropped over the course of infection. CD73 expression had dropped to half by 72 hours and the drop started to occur after 12 hours post-infection, a time point after which PMN presence in the lungs no longer correlated with control of bacterial numbers (Fig 1A) (3). The decrease of CD73 expression also occurred on circulating PMNs and bone marrow PMNs (Fig. 1C), suggesting that this was a systemic decrease and not only localized in the lungs. A recent study identified a population of PMNs in the spleen with intermediate expression of Ly6G on their surface that exhibited a lowered ability to engulf *S. pneumoniae* during i.v. infection (32). When we compared Ly6G expression, we found that CD73 positive pulmonary PMNs had significantly higher expression of Ly6G (MFI) on their surface at all the time points tested (Fig. 1D). These data show that there are changes in PMNs over the course of pneumococcal pneumonia and that low CD73 expression on PMNs may be indicative of a PMN subset that is associated with lower anti-microbial activity.

3.2 CD73 and extracellular adenosine are required for the ability of PMNs to kill *S. pneumoniae*

We previously found that EAD production and signaling is required for protection against *S. pneumoniae* lung infection (3, 33). To test if EAD production has a role in anti-pneumococcal function of PMNs, we compared *ex vivo* opsonophagocytic killing of pneumococci by PMNs isolated from the bone marrow of CD73^{-/-} or wild type C57BL/6 (WT) mice. Strikingly, CD73^{-/-} PMNs completely failed to kill *S. pneumoniae*. In fact, the presence of these PMNs promoted an increase in bacterial numbers as indicated by negative bacterial killing on the graph (Fig. 2A). To test if the inability of CD73^{-/-} PMNs to kill bacteria was due to a defect in EAD production, we added adenosine to the opsonophagocytic reactions. Adenosine levels in the sera of WT mice varied, but on average increased five-fold to 52.6 +/- 29.0 μ M upon pneumococcal infection as measured by a fluorometric kit (Fig S 2A). We found that supplementing CD73^{-/-} PMNs with EAD at 100 μ M (closer to the higher levels found in infected mice) restored the ability of these cells to kill bacteria back to levels comparable with WT PMNs. Addition of exogenous EAD had no significant effect on bacterial killing by WT PMNs (Fig 2A). However, when we pharmacologically inhibited CD39 or CD73, the enzymes required for sequential dephosphorylation of extracellular ATP to EAD, we observed a significant reduction in the ability of WT PMNs to kill *S. pneumoniae* (Fig 2B). We confirmed that the difference in killing observed was not due to difference in bacterial survival in WT versus CD73^{-/-}

sera or direct toxic effects of EAD (Fig. S2B and C) or the inhibitors on bacterial viability as previously described (3).

To test the clinical relevance of our findings, we tested the effect of CD73 inhibition on the anti-bacterial activity of PMNs from human donors. PMNs were isolated from the blood of young healthy donors and treated with the CD73 inhibitor or vehicle control *in vitro* and their ability to kill pneumococci was assessed. We found that in over half (i.e. 4 out of 7) of the donors tested, CD73 inhibition completely abrogated the ability of PMNs to kill pneumococci and in fact promoted bacterial growth in the presence of PMNs instead (Fig. 2C). These findings demonstrate that production of EAD by CD73 is required for the ability of PMNs to kill pneumococci.

3.3 Adoptive transfer of PMNs from wild type mice boosts resistance of CD73^{-/-} mice to *S. pneumoniae*

To test the role of EAD production by PMNs *in vivo*, we adoptively transferred 2.5x10⁶ PMNs isolated from WT or CD73^{-/-} mice into CD73^{-/-} mice, one hour later infected the mice with 5x10⁵ CFU of *S. pneumoniae* i.t. and then compared bacterial burdens in the lung, blood and brain at 24 hours post infection. We found that transfer of WT PMNs significantly reduced the systemic spread of pneumococci and resulted in a 50 and 5-fold reduction in blood and brain bacterial loads respectively (Fig. 3B and C) when compared to no transfer controls. In fact, bacteremia in CD73^{-/-} mice that had received WT PMNs was comparable to that observed in WT controls (Fig 3B). Transfer of WT PMNs had

no significant effect on bacterial numbers in the lungs of CD73^{-/-} recipients (Fig. 3A). Surprisingly, we found that adoptive transfer of CD73^{-/-} PMNs worsened susceptibility to infection and resulted in a ~10-fold increase in bacterial numbers in all sites (lung, blood, brain) tested (Fig. 3A-C) in CD73^{-/-} recipients when compared to no transfer controls. WT mice that received CD73^{-/-} PMNs also had a slight (but not statistically significant) increase in pulmonary bacterial numbers (Fig. 3A). This was consistent with our *in vitro* findings where bacterial numbers increased in the presence of CD73^{-/-} PMNs. These findings suggest that CD73 expression by PMNs is required and sufficient to promote resistance to *S. pneumoniae* infection.

3.4 Extracellular adenosine blocks IL-10 production by PMNs following *S. pneumoniae* infection

EAD was previously shown to play a role in regulating production of cytokines by immune cells (34) including IL-10 by macrophages (35-37). IL-10 is an anti-inflammatory cytokine whose production early on during pneumococcal infection was reported to be detrimental for host resistance (10). To test whether EAD was targeting IL-10, we compared IL-10 production by WT and CD73^{-/-} PMNs upon *in vitro* infection with *S. pneumoniae*. We found that at baseline, PMNs from both mice strains produced some IL-10 but there was no significant difference in levels. However, upon infection, within the 45 minute timeframe of our *in vitro* assays, CD73^{-/-} PMNs produced significantly more IL-10 as compared to WT PMNs (Fig. 4A). Further, while WT PMNs did not upregulate IL-10

production upon pneumococcal infection, CD73^{-/-} PMNs displayed a ~ 2.5-fold increase in IL-10 above resting baseline levels (Fig 4A and B). Importantly, this upregulation was significantly blunted upon exposure to extracellular adenosine (Fig. 4B). When we examined PMNs isolated from three human donors, we could not detect any upregulation in IL-10 mRNA in response to *S. pneumoniae* infection (data not shown). These findings show that, in contrast to wild type PMNs, CD73-deficient PMNs produce IL-10 in response to *S. pneumoniae*, and that the induction of IL-10 production upon infection can be blocked by EAD.

3.5 Pulmonary PMNs from CD73^{-/-} mice produce IL-10 early on during *S. pneumoniae* infection

Next, we wanted to test the relevance of our findings *in vivo* and assess IL-10 production during lung infection. WT B6 and CD73^{-/-} mice were infected i.t. with 5x10⁵ CFU of *S. pneumoniae* TIGR4 and IL-10 production by pulmonary PMNs was monitored following infection by intracellular cytokine staining. We focused on the first 18 hours of infection since that is when PMNs are most relevant for the control of bacterial numbers. When we gated on PMNs (Ly6G⁺; see Fig. S3 for the gating strategy), we found that a low percentage (~6%) of PMNs in the lungs of WT mice expressed IL-10 and similar to our observations *in vitro*, there was no increase in IL-10 production upon infection (Fig. 4C and D) within the first 6 hours. However, at this timepoint, we observed a significant increase in IL-10 production by pulmonary PMNs in CD73^{-/-} mice. The percentage of IL-10 producing CD73^{-/-} PMNs increased from 5% at baseline to

20% (Fig. 4C) and the amount of IL-10 produced (measured by MFI) increased approximately 1.5-fold (Fig. 4D). When we compared the number of PMNs producing IL-10, we found that in CD73^{-/-} mice, there is a significant increase in IL-10 producing PMNs above baseline by 6 hours post-infection. This increased IL-10 production by CD73^{-/-} PMNs was not due to higher bacterial numbers, as we had previously found that at 6 hours post-infection bacterial burdens in WT and CD73^{-/-} mice were equivalent and differences in bacterial control became apparent after that timepoint (3).

In contrast, in WT mice, we did not observe an increase in IL-10 producing PMNs until 18 hours following infection (Fig 4C-E). Further, as compared to CD73^{-/-} mice, WT controls had 6-fold and 2-fold fewer PMNs making IL-10 at 6 and 18 hours after lung challenge, respectively (Fig 4E). When we measured total IL-10 production in the lungs at 6 hours following infection, we found that CD73^{-/-} mice had on average more IL-10 (231.9 +/-20.51 pg/ml) as compared to WT mice (190 +/- 86.65 pg/ml), but the difference did not reach statistical significance. These findings show that upon lung infection, in the absence of CD73, IL-10 production by pulmonary PMNs is higher and occurs more rapidly.

3.6 Blocking IL-10 prior to infection rescues the susceptibility of CD73^{-/-} mice to pneumococcal lung infection

To test whether the early increase in IL-10 production by PMNs in CD73^{-/-} mice contribute to their susceptibility to infection, we treated the mice with either isotype control or an IL-10 blocking antibody 2 hours prior to infection. Mice were

then challenged i.t. with 5×10^5 CFU of *S. pneumoniae*, and bacterial burdens in the lung and blood were determined two days post-infection. Blocking IL-10 prior to infection significantly boosted the resistance of CD73^{-/-} mice resulting in a 20 and 24-fold reduction in bacterial numbers in the lung and blood respectively as compared to isotype treated controls (Fig 5A and B). Importantly, blocking IL-10 in CD73^{-/-} mice rendered bacterial burdens in these mice indistinguishable from those of WT mice (Fig 5A and B). In WT mice, blocking IL-10 prior to infection had no significant effect on bacterial burden (Fig 5A and B). Our data suggest that the increased susceptibility of CD73^{-/-} mice during pneumococcal infection is in part mediated by increased IL-10 production.

3.7 IL-10 impairs the ability of PMNs to kill *S. pneumoniae*

Although the role of IL-10 during *S. pneumoniae* infection in mice is well established (10-12, 38), its effect on PMN anti-pneumococcal function has not been elucidated. To test that, WT PMNs were treated with either recombinant IL-10 or IL-10 blocking antibody and their ability to kill pneumococci measured in our *in vitro* opsonophagocytic assay. We found that addition of IL-10 abrogated the ability of WT PMNs to kill pneumococci while blocking this cytokine slightly boosted the anti-bacterial efficiency of PMNs (Fig 5C).

To test whether the anti-bacterial activity of CD73^{-/-} PMNs can be rescued by targeting IL-10, we treated the PMNs with the IL-10 blocking antibody and performed the opsonophagocytic assay. We found that blocking IL-10 restored the pneumococcal killing ability of CD73^{-/-} PMNs to WT levels (Fig 5C). To test if

the ability of adenosine to rescue CD73^{-/-} PMN function was dependent on inhibiting IL-10, we added recombinant IL-10 to CD73^{-/-} PMNs supplemented with adenosine. We found that the addition of recombinant IL-10 had no discernable effect on bacterial killing by CD73^{-/-} PMNs, consistent with the (already high) levels of IL-10 produced by these cells (Fig 5C). However, the addition of IL-10 prevented the ability of adenosine to boost the anti-microbial function of these cells (Fig 5C). These findings demonstrate that EAD's ability to inhibit IL-10 production is crucial for the anti-pneumococcal function of PMNs.

3.8 CD73 has no effect on PMN viability, bacterial uptake, intracellular killing or enzymes in primary granules

We next wanted to identify how CD73, EAD and IL-10 were regulating the ability of PMNs to kill *S. pneumoniae*. Bacterial uptake was previously shown to be important for killing by PMNs (4, 5). To test if EAD production was affecting bacterial phagocytosis, we used a gentamicin-protection assay where gentamicin was added following PMN infection with opsonized pneumococci to kill any extracellular bacteria. We found that the pneumococcal pore forming toxin pneumolysin (PLY) underestimated the true numbers of intracellular bacteria (Fig. S4A) in the gentamicin protection assays, but had no effect on susceptibility to the antibiotic (Fig. S4B) or overall opsonophagocytic killing by PMNs as previously described (39) (Fig. S4C). We therefore proceeded with using *S. pneumoniae* Δ PLY to compare phagocytosis between WT and CD73^{-/-} PMNs. To differentiate uptake from intracellular killing, we looked early at 10 minutes post

infection, and found no significant difference in the percentage of engulfed bacteria between the different mouse strains (Fig. S4D). We also found that the engulfed bacteria were very efficiently killed by both WT and CD73^{-/-} PMNs (Fig. S4E). We observed 50% and 100% of the engulfed inoculum being killed by PMNs at 30 and 90 minutes post-uptake respectively. We also tested the effect of IL-10 on the association of PMNs with GFP-expressing pneumococci and found that neither addition nor blocking of IL-10 altered association (data not shown). These findings suggest that CD73/EAD do not affect bacterial uptake or intracellular killing by PMNs.

Components of PMN primary granules including serine protease such as cathepsin G (CG) and neutrophil elastase (NE) (4, 5) as well as myeloperoxidase (MPO) (40) were shown to be important for the ability of PMNs to kill *S. pneumoniae*. We therefore measured if CD73, EAD and IL-10 altered the activities of serine proteases Cathepsin G and NE. We were unable to detect Cathepsin G enzymatic activity either at baseline or upon pneumococcal infection in any of the samples we collected. NE activity was easily detected; however, we found no significant difference in NE activity between WT and CD73^{-/-} PMNs at baseline or upon infection. Further, addition of adenosine, recombinant IL-10 or the IL-10 blocking antibody did not alter this response (Fig S5A). When we measured MPO levels, we found that pneumococcal infection significantly increased the amounts of intracellular and released MPO (Fig S5B and C) as previously reported (40). However, there was no difference in the amount of MPO between WT and CD73^{-/-} PMNs, nor were its levels altered by blocking or

adding IL-10 (Fig S5B and C). These findings show that CD73, EAD and IL-10 had no effect on the primary granule components NE or MPO.

It was previously reported that IL-10 producing PMNs were apoptotic (41). Since cellular death pathways including apoptosis and necrosis are known to play a role in the anti-bacterial function of PMNs (42), we compared the percentage of apoptotic and necrotic cells using Annexin V and propidium iodide staining and flow cytometry. We found that as expected (43), pneumococcal infection induced pore formation and necrosis of PMNs (PI and Annexin V double positive cells) (Fig S6). However, there was no difference in viability of PMNs at baseline or upon infection between WT and CD73^{-/-} PMNs. Addition or inhibition of IL-10 did not further alter the percentage of necrotic PMNs (Fig S6). These findings suggest that CD73, EAD and IL-10 do not affect PMN viability.

3.9 CD73 and IL-10 regulate extracellular ROS production by PMNs upon *S. pneumoniae* infection

IL-10 was reported to down-regulate reactive oxygen species (ROS) production by PMNs (18). To determine whether the CD73/IL-10 axis regulated ROS production upon pneumococcal infection, we first compared production of ROS by WT and CD73^{-/-} PMNs. We first measured ROS levels using luminol, which is cell permeable and detects intracellular ROS. We found that the infection up regulated ROS production rapidly within minutes to more than 50-fold increase around the peak of the response at the 25 minute mark in both strains of mice (Fig. 6A). There was no significant difference in intracellular ROS

levels by WT vs CD73^{-/-} PMNs in response to pneumococcal infection, consistent with our findings that bacterial uptake and intracellular killing was not affected by CD73.

As PLY forms pores that can lead to the release of products from PMNs, we next examined levels of ROS using isoluminol and HRP which can detect extracellular ROS. In uninfected PMNs, no ROS production was observed (Fig. 6B). However, upon exposure to pneumococci, ROS was rapidly induced by PMNs from both strains of mice. This response was immediate and peaked within the first five minutes of infection and waned over time (Fig. 6B) as previously described (24). Importantly, during the first 10 minutes, PMNs from B6 mice released significantly higher levels of extracellular ROS than CD73^{-/-} PMNs, producing 3-fold higher levels of ROS at the peak of the response (Fig. Fig. 6B at the 5 minute mark). Extracellular ROS levels by PMNs in response to the positive control PMA was not different between mouse strains (not shown), indicating that the blunted response observed in CD73^{-/-} PMNs was not due to a general defect in ROS production, but rather was specific to pneumococcal infection.

To determine if IL-10 had a role in production of ROS by PMNs, we added recombinant IL-10 to B6 PMNs. We found that this cytokine significantly blunted the magnitude of the ROS response during pneumococcal infection, which is consistent with its reported anti-inflammatory role (18) (Fig. 6C). Next we tested whether ROS production by CD73^{-/-} PMNs upon infection can be rescued by treating the PMNs with the IL-10 blocking antibody. We found that blocking IL-10

significantly boosted extracellular ROS levels in infected CD73^{-/-} PMNs, resulting in around a 2-fold increase at the peak of the response at 5 minutes post infection (Fig. 6D). Similarly, addition of adenosine significantly boosted ROS responses by infected CD73^{-/-} PMNs (Fig. 6D). Taken together, these data demonstrate that inhibition of IL-10 production by CD73 is important for an optimal ROS response by PMNs during *S. pneumoniae* infection.

3.10 ROS detoxification is important for the ability of *S. pneumoniae* to resist killing by WT but not CD73^{-/-} PMNs

The role of ROS production by NADPH oxidase in the function of PMNs against pneumococci is unclear (32, 44). Consistent with previous reports (4), when we treated PMNs with DPI, which inhibits ROS production by flavoenzymes such as NADPH oxidase, we found no effect on the ability of these cells to kill *S. pneumoniae* (Fig 7A). However, when we used ascorbic acid, an anti-oxidant that scavenges ROS (45) or EUK 134 which detoxifies ROS by mimicking the activity of superoxide dismutase and catalase (46), the ability of WT PMNs to kill *S. pneumoniae* was completely abrogated (Fig 7A). We also tested *S. pneumoniae* that lack manganese-dependent superoxide dismutase (Δ sodA), the major SOD enzyme in *S. pneumoniae* that degrades superoxide radicals (47). We found that this bacterial mutant was significantly more susceptible to killing by PMNs from C57BL/6 mice as compared to wildtype *S. pneumoniae* (Fig 7A and B). Addition of EUK 134 or ascorbic acid reversed the susceptibility of Δ sodA *S. pneumoniae* to killing by PMNs (Fig 7A). None of the compounds tested had a direct effect on

bacterial viability (not shown). These findings suggest that *S. pneumoniae* are susceptible to killing by ROS produced by PMNs.

When we tested CD73^{-/-} PMNs, we did not observe any increase in killing of Δ sodA *S. pneumoniae* (Fig 7B), which was expected given the blunted ROS response by these PMNs. To test if the presence of ROS is important for the ability of adenosine to rescue CD73^{-/-} PMN function, we used EUK 134 or ascorbic acid. We found that the ability of adenosine to boost the anti-pneumococcal activity of these cells was lost when ROS was removed (Fig 7C). These findings suggest that the presence of ROS is important for EAD's ability to promote the anti-pneumococcal function of PMNs.

4. Discussion

There is mounting evidence that PMNs are plastic and display phenotypic and functional heterogeneity under different disease states (48). These range from traditional pro-inflammatory subsets during infections (13, 48) to B-helper PMNs (32, 49) to suppressive phenotypes in tumor microenvironments (50, 51) and anti-inflammatory in response certain pathogens and microbial products (13-16, 52-54). In the context of pneumococcal pneumonia, we previously found that the efficacy of PMNs during the course of disease changes from clearing bacteria early on to promoting infection at later time points (3). Here we show that this shift away from an anti-microbial phenotype is associated with a decrease in CD73 expression on PMNs. Using *in vitro* bacterial killing assays and adoptive transfer of PMNs into CD73^{-/-} recipients, we found that CD73 expression on

PMNs was crucial for the ability of these cells to kill *S. pneumoniae* and mediate protection during lung infection *in vivo*. In fact, loss of CD73 expression on PMNs seem to actively promote bacterial growth as *S. pneumoniae* grew in the presence of CD73^{-/-} PMNs *in vitro* and adoptive transfer of CD73^{-/-} PMNs worsened the infection resulting in increased bacterial burdens in recipient mice. Importantly, inhibition of CD73 *in vitro* abrogated the ability of human PMNs to kill pneumococci in 60% of donors tested, highlighting the clinical relevance of this pathway. These findings suggest that CD73 regulates the PMN antimicrobial phenotype.

During systemic infection with *S. pneumoniae*, a subset of immature PMNs with a lower expression of surface Ly6G that exhibited a low ability to bind bacteria was observed immobilized in the spleen (32). When we followed Ly6G expression on PMNs (gated on Ly6G positive cells) over time, we noticed it changed over time where we observed an increase in Ly6G expression on pulmonary PMNs recruited at the 6 hour time point followed by a subsequent decrease after that. However, we observed that CD73-negative PMNs in the lungs had significantly lower amounts of Ly6G on their surface as compared to their CD73⁺ counterparts at all time points suggesting that they could denote a less mature subset. We believe that these CD73-negative pulmonary PMNs migrate from the circulation after originating from the bone marrow, as the reduced expression of CD73 following infection was also observed on circulating PMNs as well as the PMN pool in the bone marrow.

In exploring mechanisms of how CD73 controls the PMN antimicrobial phenotype, we found that it inhibited IL-10 production in response to pneumococcal infection. In wild type mice, we did not see any up regulation in IL-10 production by PMNs early in infection. IL-10 producing PMNs only started to accumulate at the 18h time point that coincided with a decrease in CD73 on pulmonary PMNs and their inability to control bacterial numbers (3). In contrast, PMNs from CD73^{-/-} mice up regulated IL-10 production early on within 6 hours of infection. Our IL-10 blocking experiments both *in vitro* and *in vivo* suggest that this early IL-10 production impaired the ability of CD73^{-/-} mice to control infection. Our data align with previous reports that administration of IL-10 early in infection impairs the ability of the host to control pneumococcal numbers (10). However, studies have also found that mice that lack IL-10 had exacerbated PMN influx in their lungs (12, 38) and succumbed to the infection despite having lower bacterial burden in their organs (12). These findings suggest that early production of IL-10 is deleterious for the host's ability to control the infection, however, it may be required later on for resolution of inflammation and return to homeostasis. Therefore, the eventual accumulation of IL-10 producing PMNs in wild type mice we observed here may be beneficial in resolution of pulmonary inflammation observed in healthy hosts (3).

Murine PMNs have been described to produce IL-10 in sepsis models and in response to several bacterial infections such as *Escherichia coli*, *Shigella flexneri* (16) and *Staphylococcus aureus* (13) as well as parasitic infections such as *Leishmania major* (14) and *Trypanosoma cruzi* (15). In contrast, IL-10

production by pulmonary PMNs was actively repressed during *Mycobacterium tuberculosis* (55). In this study, we did not detect an up regulation in IL-10 production by PMNs in response to *S. pneumoniae* infection in wild type mice either *in vivo* during lung challenge or *in vitro* in response to direct bacterial infection. Further, we were unable to detect an increase in IL-10 mRNA in PMNs isolated from human donors in response to stimulation with *S. pneumoniae*. This fits with previous studies demonstrating that resting human PMNs have histone modifications at the IL-10 locus rendering it transcriptionally silent (56) and that induction of IL-10 production by PMNs requires further stimulation such as direct contact with LPS-treated Tregs or IL-10 itself that promote histone posttranslational modifications that can activate IL-10 transcription (41).

Our data suggests that IL-10 production by PMNs in response to *S. pneumoniae* is actively suppressed by EAD production by CD73. This is in contrast to what has been described for macrophages. Adenosine induced IL-10 production by macrophages in response to LPS stimulation (36, 37) or *E. coli* infection (35) by acting via the A2A or A2B receptor to facilitate binding of transcription factors to the IL-10 locus and enhancing transcription (35) or via posttranscriptional modifications of the 3'-UTR that facilitated translation (36) respectively. These differences observed could be accounted for by the cell type i.e. macrophages vs. PMNs or the stimulation where the macrophage studies have been performed with Gram-negative bacteria and their products (LPS) while we are examining responses to a Gram-positive organism.

Phagocytosis and serine proteases were shown to contribute to the ability of PMNs kill *S. pneumoniae* (4). In exploring how the CD73/IL-10 axis regulated PMN anti-pneumococcal activity we found that apoptosis, bacterial uptake and intracellular killing and production of anti-microbial Neutrophil Elastase and Myeloperoxidase were not affected by this pathway. Rather, inhibition of IL-10 production by CD73 was crucial for optimal production of extracellular ROS by PMNs upon *S. pneumoniae* infection. Importantly, the presence of ROS was required for the ability of adenosine to rescue bacterial killing by CD73^{-/-} PMNs. This is in line with previous findings that adenosine signaling via the A1 receptor enhanced superoxide production by PMNs in response to antibody coated erythrocytes (57) and that IL-10 blunted PMN superoxide production in response to PMA and *C. albicans* hyphae (18, 19).

We found here that the bacterial infection triggered ROS production by PMNs similar to what has been reported (24, 58). ROS detoxification is crucial for pneumococcal survival in host environments (59) as bacterial mutants lacking components that detoxify ROS die more readily in response to oxidative stress (60-63). Similarly, we found that Δ sodA *S. pneumoniae*, which lacks the enzyme superoxide dismutase, a manganese-dependent enzyme that detoxifies superoxide radicals (47), is more susceptible to killing by PMNs. Importantly, this susceptibility was reversed upon the exogenous addition of compounds that remove ROS. This highlighted the importance of ROS detoxification for the ability of *S. pneumoniae* to resist killing by PMNs. NADPH oxidase is a major source of ROS in PMNs (64). However, when we used DPI to inhibit NADPH oxidase, we

saw no effect on bacterial killing by wildtype PMNs. This is in line with previous work showing that mice lacking components of the NADPH oxidase are not more susceptible to pneumococcal lung infection (32, 44) and that using DPI to inhibit respiratory burst has no effect on the ability of PMNs to kill *S. pneumoniae* (4). Intriguingly, when we used EUK134 and ascorbic acid to detoxify or scavenge ROS respectively (45, 46), the ability of PMNs to kill *S. pneumoniae* was significantly impaired. These findings suggest that ROS is important for bacterial killing, however, NADPH oxidase may not be the only source of ROS in PMNs. Cellular ROS can be produced from several sources other than NADPH oxidase including the mitochondrial respiratory chain, lipoxygenases, cyclooxygenases among others (65). In fact, previous work found that the NADPH oxidase inhibitor DPI reduced, but did not completely abrogate ROS production by PMNs in response to pneumococcal infection (40). Pneumococcal infection is known to activate cellular lipoxygenases and cyclooxygenases and these enzymes which are expressed by leukocytes but are not inhibited by DPI (6, 66-69), may act as an alternate sources of ROS.

Adenosine is a well-known regulator of PMN function and is known to regulate PMN recruitment, release of inflammatory cytokines, phagocytic capacity and oxidative burst (34). However, the majority of those studies have been conducted in the context of sterile inflammation or in response to *in vitro* stimulation by inflammatory mediators such as fMLP, LPS, TNF or inert particles (34). The role of the EAD pathway in PMN response to infections is now better appreciated and was shown to play a role in host resistance during pulmonary

infections with influenza A virus (70, 71), *Klebsiella pneumoniae* (72) and *S. pneumoniae* (3). Here, we identified the mechanisms by which EAD production by CD73 regulated PMN anti-pneumococcal function and further found it was relevant for the function of PMNs from human donors. This may be relevant for incorporating clinically available adenosine-based drugs to combat pneumococcal pneumonia and other serious lung infections in the future.

Authorship

NS and JNL conducted research, analyzed data and wrote the paper. MB, EYIT, JHY and SER conducted research, JML provided essential expertise and reviewed the paper. ENBG designed research, conducted research, analyzed data, wrote the paper and had primary responsibility for final content.

Acknowledgments

We would like to acknowledge Andrew Camilli for bacterial strains and Joan Mecsas for ROS detection protocols. This work was supported by National Institute of Health grant R00AG051784 to ENBG.

Conflict of Interest Disclosure

None

References

- 822 1. Garvy BA, Harmsen AG. The importance of neutrophils in resistance to
823 pneumococcal pneumonia in adult and neonatal mice. *Inflammation*.
824 1996;20(5):499-512. Epub 1996/10/01. PubMed PMID: 8894714.
- 825 2. Rolston KV. The spectrum of pulmonary infections in cancer patients.
826 *Current opinion in oncology*. 2001;13(4):218-23. Epub 2001/06/29. PubMed
827 PMID: 11429477.
- 828 3. Bou Ghanem EN, Clark S, Roggensack SE, McIver SR, Alcaide P,
829 Haydon PG, et al. Extracellular Adenosine Protects against *Streptococcus*
830 *pneumoniae* Lung Infection by Regulating Pulmonary Neutrophil Recruitment.
831 *PLoS pathogens*. 2015;11(8):e1005126. Epub 2015/08/28. doi:
832 10.1371/journal.ppat.1005126. PubMed PMID: 26313746; PubMed Central
833 PMCID: PMC4552087.
- 834 4. Standish AJ, Weiser JN. Human neutrophils kill *Streptococcus*
835 *pneumoniae* via serine proteases. *J Immunol*. 2009;183(4):2602-9. Epub
836 2009/07/22. doi: 10.4049/jimmunol.0900688. PubMed PMID: 19620298.
- 837 5. Hahn I, Klaus A, Janze AK, Steinwede K, Ding N, Bohling J, et al.
838 Cathepsin G and neutrophil elastase play critical and nonredundant roles in lung-
839 protective immunity against *Streptococcus pneumoniae* in mice. *Infect Immun*.
840 2011;79(12):4893-901. Epub 2011/09/14. doi: 10.1128/IAI.05593-11. PubMed
841 PMID: 21911460; PubMed Central PMCID: PMC3232647.
- 842 6. Bhowmick R, Tin Maung NH, Hurley BP, Ghanem EB, Gronert K,
843 McCormick BA, et al. Systemic disease during *Streptococcus pneumoniae* acute
844 lung infection requires 12-lipoxygenase-dependent inflammation. *J Immunol*.

- 2013;191(10):5115-23. Epub 2013/10/04. doi: 10.4049/jimmunol.1300522.
PubMed PMID: 24089193; PubMed Central PMCID: PMC3836588.
7. Bou Ghanem EN, Clark S, Du X, Wu D, Camilli A, Leong JM, et al. The
alpha-tocopherol form of vitamin E reverses age-associated susceptibility to
streptococcus pneumoniae lung infection by modulating pulmonary neutrophil
recruitment. J Immunol. 2015;194(3):1090-9. Epub 2014/12/17. doi:
10.4049/jimmunol.1402401. PubMed PMID: 25512603; PubMed Central PMCID:
PMC4834212.
8. Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele CJ, Resta R, Morote-
Garcia JC, et al. Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage
during hypoxia. The Journal of experimental medicine. 2004;200(11):1395-405.
Epub 2004/12/08. doi: 10.1084/jem.20040915. PubMed PMID: 15583013;
PubMed Central PMCID: PMC1237012.
9. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors:
therapeutic aspects for inflammatory and immune diseases. Nature reviews Drug
discovery. 2008;7(9):759-70. Epub 2008/09/02. doi: 10.1038/nrd2638. PubMed
PMID: 18758473; PubMed Central PMCID: PMC2568887.
10. van der Poll T, Marchant A, Keogh CV, Goldman M, Lowry SF. Interleukin-
10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis.
1996;174(5):994-1000. Epub 1996/11/01. PubMed PMID: 8896500.
11. van der Sluijs KF, van Elden LJ, Nijhuis M, Schuurman R, Pater JM,
Florquin S, et al. IL-10 is an important mediator of the enhanced susceptibility to

- 867 pneumococcal pneumonia after influenza infection. *J Immunol.*
868 2004;172(12):7603-9. Epub 2004/06/10. PubMed PMID: 15187140.
- 869 12. Penaloza HF, Nieto PA, Munoz-Durango N, Salazar-Echegarai FJ, Torres
870 J, Parga MJ, et al. Interleukin-10 plays a key role in the modulation of neutrophils
871 recruitment and lung inflammation during infection by *Streptococcus*
872 *pneumoniae*. *Immunology.* 2015;146(1):100-12. Epub 2015/06/03. doi:
873 10.1111/imm.12486. PubMed PMID: 26032199; PubMed Central PMCID:
874 PMC4552505.
- 875 13. Tsuda Y, Takahashi H, Kobayashi M, Hanafusa T, Herndon DN, Suzuki F.
876 Three different neutrophil subsets exhibited in mice with different susceptibilities
877 to infection by methicillin-resistant *Staphylococcus aureus*. *Immunity.*
878 2004;21(2):215-26. Epub 2004/08/17. doi: 10.1016/j.immuni.2004.07.006.
879 PubMed PMID: 15308102.
- 880 14. Charmoy M, Megnekou R, Allenbach C, Zweifel C, Perez C, Monnat K, et
881 al. *Leishmania major* induces distinct neutrophil phenotypes in mice that are
882 resistant or susceptible to infection. *J Leukoc Biol.* 2007;82(2):288-99. Epub
883 2007/04/24. doi: 10.1189/jlb.0706440. PubMed PMID: 17449725.
- 884 15. Tosello Boari J, Amezcua Vesely MC, Bermejo DA, Ramello MC, Montes
885 CL, Cejas H, et al. IL-17RA signaling reduces inflammation and mortality during
886 *Trypanosoma cruzi* infection by recruiting suppressive IL-10-producing
887 neutrophils. *PLoS pathogens.* 2012;8(4):e1002658. Epub 2012/05/12. doi:
888 10.1371/journal.ppat.1002658. PubMed PMID: 22577359; PubMed Central
889 PMCID: PMC3343119.

- 890 16. Zhang X, Majlessi L, Deriaud E, Leclerc C, Lo-Man R. Coactivation of Syk
891 kinase and MyD88 adaptor protein pathways by bacteria promotes regulatory
892 properties of neutrophils. *Immunity*. 2009;31(5):761-71. Epub 2009/11/17. doi:
893 10.1016/j.immuni.2009.09.016. PubMed PMID: 19913447.
- 894 17. Kasten KR, Muenzer JT, Caldwell CC. Neutrophils are significant
895 producers of IL-10 during sepsis. *Biochemical and biophysical research
896 communications*. 2010;393(1):28-31. Epub 2010/01/26. doi:
897 10.1016/j.bbrc.2010.01.066. PubMed PMID: 20097159; PubMed Central PMCID:
898 PMC2830356.
- 899 18. Laichalk LL, Danforth JM, Standiford TJ. Interleukin-10 inhibits neutrophil
900 phagocytic and bactericidal activity. *FEMS immunology and medical
901 microbiology*. 1996;15(4):181-7. Epub 1996/10/01. doi: 10.1111/j.1574-
902 695X.1996.tb00084.x. PubMed PMID: 8908479.
- 903 19. Roilides E, Katsifa H, Tsaparidou S, Stergiopoulou T, Panteliadis C,
904 Walsh TJ. Interleukin 10 suppresses phagocytic and antihyphal activities of
905 human neutrophils. *Cytokine*. 2000;12(4):379-87. Epub 2000/05/11. doi:
906 10.1006/cyto.1999.0567. PubMed PMID: 10805220.
- 907 20. Greene NG, Narciso AR, Filipe SR, Camilli A. Peptidoglycan Branched
908 Stem Peptides Contribute to *Streptococcus pneumoniae* Virulence by Inhibiting
909 Pneumolysin Release. *PLoS pathogens*. 2015;11(6):e1004996. Epub
910 2015/06/27. doi: 10.1371/journal.ppat.1004996. PubMed PMID: 26114646;
911 PubMed Central PMCID: PMC4483231.

- 912 21. Dalia AB, McDonough E, Camilli A. Multiplex genome editing by natural
913 transformation. *Proc Natl Acad Sci U S A*. 2014;111(24):8937-42. Epub
914 2014/06/04. doi: 10.1073/pnas.1406478111. PubMed PMID: 24889608; PubMed
915 Central PMCID: PMCPMC4066482.
- 916 22. Swamydas M, Lionakis MS. Isolation, purification and labeling of mouse
917 bone marrow neutrophils for functional studies and adoptive transfer
918 experiments. *Journal of visualized experiments : JoVE*. 2013(77):e50586. Epub
919 2013/07/31. doi: 10.3791/50586. PubMed PMID: 23892876; PubMed Central
920 PMCID: PMC3732092.
- 921 23. Lysenko ES, Clarke TB, Shchepetov M, Ratner AJ, Roper DI, Dowson
922 CG, et al. Nod1 signaling overcomes resistance of *S. pneumoniae* to
923 opsonophagocytic killing. *PLoS pathogens*. 2007;3(8):e118. Epub 2007/08/29.
924 doi: 10.1371/journal.ppat.0030118. PubMed PMID: 17722978; PubMed Central
925 PMCID: PMC1950946.
- 926 24. Martner A, Dahlgren C, Paton JC, Wold AE. Pneumolysin released during
927 *Streptococcus pneumoniae* autolysis is a potent activator of intracellular oxygen
928 radical production in neutrophils. *Infect Immun*. 2008;76(9):4079-87. Epub
929 2008/06/19. doi: 10.1128/IAI.01747-07. PubMed PMID: 18559434; PubMed
930 Central PMCID: PMC2519426.
- 931 25. Dahlgren C, Follin P, Johansson A, Lock R, Orselius K. Localization of the
932 luminol-dependent chemiluminescence reaction in human granulocytes. *Journal*
933 *of bioluminescence and chemiluminescence*. 1989;4(1):263-6. Epub 1989/07/01.
934 doi: 10.1002/bio.1170040137. PubMed PMID: 2552755.

- 935 26. Dahlgren C, Karlsson A. Respiratory burst in human neutrophils. Journal
936 of immunological methods. 1999;232(1-2):3-14. Epub 2000/01/05. PubMed
937 PMID: 10618505.
- 938 27. Rajecky M, Lojek A, Ciz M. Differentiating between intra- and extracellular
939 chemiluminescence in diluted whole-blood samples. International journal of
940 laboratory hematology. 2012;34(2):136-42. Epub 2011/08/13. doi:
941 10.1111/j.1751-553X.2011.01370.x. PubMed PMID: 21834798.
- 942 28. Mook-Kanamori B, Geldhoff M, Troost D, van der Poll T, van de Beek D.
943 Characterization of a pneumococcal meningitis mouse model. BMC infectious
944 diseases. 2012;12:71. Epub 2012/03/30. doi: 10.1186/1471-2334-12-71. PubMed
945 PMID: 22455545; PubMed Central PMCID: PMC3364848.
- 946 29. Ocuin LM, Bamboat ZM, Balachandran VP, Cavnar MJ, Obaid H, Plitas G,
947 et al. Neutrophil IL-10 suppresses peritoneal inflammatory monocytes during
948 polymicrobial sepsis. J Leukoc Biol. 2011;89(3):423-32. Epub 2010/11/26. doi:
949 10.1189/jlb.0810479. PubMed PMID: 21106642; PubMed Central PMCID:
950 PMCPMC3040467.
- 951 30. Bou Ghanem EN, Lee JN, Joma BH, Meydani SN, Leong JM, Panda A.
952 The Alpha-Tocopherol Form of Vitamin E Boosts Elastase Activity of Human
953 PMNs and Their Ability to Kill Streptococcus pneumoniae. Frontiers in cellular
954 and infection microbiology. 2017;7:161. Epub 2017/05/19. doi:
955 10.3389/fcimb.2017.00161. PubMed PMID: 28516066; PubMed Central PMCID:
956 PMC5413490.

- 957 31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
958 real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods*.
959 2001;25(4):402-8. Epub 2002/02/16. doi: 10.1006/meth.2001.1262. PubMed
960 PMID: 11846609.
- 961 32. Deniset JF, Surewaard BG, Lee WY, Kubes P. Splenic Ly6G(high) mature
962 and Ly6G(int) immature neutrophils contribute to eradication of *S. pneumoniae*.
963 *The Journal of experimental medicine*. 2017;214(5):1333-50. Epub 2017/04/21.
964 doi: 10.1084/jem.20161621. PubMed PMID: 28424248; PubMed Central PMCID:
965 PMC5413339.
- 966 33. Bhalla M, Hui Yeoh J, Lamneck C, Herring SE, Tchalla EYI, Heinzinger
967 LR, et al. A1 adenosine receptor signaling reduces *Streptococcus pneumoniae*
968 adherence to pulmonary epithelial cells by targeting expression of platelet-
969 activating factor receptor. *Cellular microbiology*. 2019:e13141. Epub 2019/11/12.
970 doi: 10.1111/cmi.13141. PubMed PMID: 31709673.
- 971 34. Barletta KE, Ley K, Mehrad B. Regulation of neutrophil function by
972 adenosine. *Arteriosclerosis, thrombosis, and vascular biology*. 2012;32(4):856-
973 64. Epub 2012/03/17. doi: 10.1161/ATVBAHA.111.226845. PubMed PMID:
974 22423037; PubMed Central PMCID: PMC3353547.
- 975 35. Csoka B, Nemeth ZH, Virag L, Gergely P, Leibovich SJ, Pacher P, et al.
976 A2A adenosine receptors and C/EBPbeta are crucially required for IL-10
977 production by macrophages exposed to *Escherichia coli*. *Blood*.
978 2007;110(7):2685-95. Epub 2007/05/26. doi: 10.1182/blood-2007-01-065870.
979 PubMed PMID: 17525287; PubMed Central PMCID: PMC1988939.

- 980 36. Nemeth ZH, Lutz CS, Csoka B, Deitch EA, Leibovich SJ, Gause WC, et al.
981 Adenosine augments IL-10 production by macrophages through an A2B
982 receptor-mediated posttranscriptional mechanism. J Immunol.
983 2005;175(12):8260-70. Epub 2005/12/13. PubMed PMID: 16339566; PubMed
984 Central PMCID: PMC2000336.
- 985 37. Cohen HB, Briggs KT, Marino JP, Ravid K, Robson SC, Mosser DM. TLR
986 stimulation initiates a CD39-based autoregulatory mechanism that limits
987 macrophage inflammatory responses. Blood. 2013;122(11):1935-45. Epub
988 2013/08/03. doi: 10.1182/blood-2013-04-496216. PubMed PMID: 23908469;
989 PubMed Central PMCID: PMC3772500.
- 990 38. Williams AE, Jose RJ, Brown JS, Chambers RC. Enhanced inflammation
991 in aged mice following infection with *Streptococcus pneumoniae* is associated
992 with decreased IL-10 and augmented chemokine production. American journal of
993 physiology Lung cellular and molecular physiology. 2015;308(6):L539-49. Epub
994 2015/01/18. doi: 10.1152/ajplung.00141.2014. PubMed PMID: 25595646;
995 PubMed Central PMCID: PMC4360060.
- 996 39. Benton KA, Everson MP, Briles DE. A pneumolysin-negative mutant of
997 *Streptococcus pneumoniae* causes chronic bacteremia rather than acute sepsis
998 in mice. Infect Immun. 1995;63(2):448-55. Epub 1995/02/01. PubMed PMID:
999 7822009; PubMed Central PMCID: PMC173016.
- 1000 40. Xiang Y, Jin C, Wang W, Wang Z, Huang Y, Fan F, et al. The critical role
1001 of myeloperoxidase in *Streptococcus pneumoniae* clearance and tissue damage

1002 during mouse acute otitis media. *Innate immunity*. 2017;23(3):296-306. Epub
1003 2017/04/01. doi: 10.1177/1753425917693907. PubMed PMID: 28359218.

1004 41. Lewkowicz N, Mycko MP, Przygodzka P, Cwiklinska H, Cichalewska M,
1005 Matysiak M, et al. Induction of human IL-10-producing neutrophils by LPS-
1006 stimulated Treg cells and IL-10. *Mucosal immunology*. 2016;9(2):364-78. Epub
1007 2015/07/30. doi: 10.1038/mi.2015.66. PubMed PMID: 26220165.

1008 42. McCracken JM, Allen LA. Regulation of human neutrophil apoptosis and
1009 lifespan in health and disease. *Journal of cell death*. 2014;7:15-23. Epub
1010 2014/10/04. doi: 10.4137/JCD.S11038. PubMed PMID: 25278783; PubMed
1011 Central PMCID: PMC4167320.

1012 43. Zysk G, Bejo L, Schneider-Wald BK, Nau R, Heinz H. Induction of
1013 necrosis and apoptosis of neutrophil granulocytes by *Streptococcus pneumoniae*.
1014 *Clinical and experimental immunology*. 2000;122(1):61-6. Epub 2000/09/30.
1015 PubMed PMID: 11012619; PubMed Central PMCID: PMC1905755.

1016 44. Marriott HM, Jackson LE, Wilkinson TS, Simpson AJ, Mitchell TJ, Buttle
1017 DJ, et al. Reactive oxygen species regulate neutrophil recruitment and survival in
1018 pneumococcal pneumonia. *American journal of respiratory and critical care*
1019 *medicine*. 2008;177(8):887-95. Epub 2008/01/19. doi: 10.1164/rccm.200707-
1020 990OC. PubMed PMID: 18202350; PubMed Central PMCID: PMC2643216.

1021 45. Guaiquil VH, Vera JC, Golde DW. Mechanism of vitamin C inhibition of
1022 cell death induced by oxidative stress in glutathione-depleted HL-60 cells. *The*
1023 *Journal of biological chemistry*. 2001;276(44):40955-61. Epub 2001/09/05. doi:
1024 10.1074/jbc.M106878200. PubMed PMID: 11533037.

- 1025 46. Rong Y, Doctrow SR, Tocco G, Baudry M. EUK-134, a synthetic
1026 superoxide dismutase and catalase mimetic, prevents oxidative stress and
1027 attenuates kainate-induced neuropathology. *Proc Natl Acad Sci U S A*.
1028 1999;96(17):9897-902. Epub 1999/08/18. doi: 10.1073/pnas.96.17.9897.
1029 PubMed PMID: 10449791; PubMed Central PMCID: PMCPMC22307.
- 1030 47. Yesilkaya H, Kadioglu A, Gingles N, Alexander JE, Mitchell TJ, Andrew
1031 PW. Role of manganese-containing superoxide dismutase in oxidative stress and
1032 virulence of *Streptococcus pneumoniae*. *Infect Immun*. 2000;68(5):2819-26.
1033 Epub 2000/04/18. doi: 10.1128/iai.68.5.2819-2826.2000. PubMed PMID:
1034 10768978; PubMed Central PMCID: PMCPMC97493.
- 1035 48. Deniset JF, Kubes P. Neutrophil heterogeneity: Bona fide subsets or
1036 polarization states? *J Leukoc Biol*. 2018;103(5):829-38. Epub 2018/02/21. doi:
1037 10.1002/JLB.3RI0917-361R. PubMed PMID: 29462505.
- 1038 49. Puga I, Cols M, Barra CM, He B, Cassis L, Gentile M, et al. B cell-helper
1039 neutrophils stimulate the diversification and production of immunoglobulin in the
1040 marginal zone of the spleen. *Nature immunology*. 2011;13(2):170-80. Epub
1041 2011/12/27. doi: 10.1038/ni.2194. PubMed PMID: 22197976; PubMed Central
1042 PMCID: PMC3262910.
- 1043 50. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al.
1044 Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus
1045 "N2" TAN. *Cancer cell*. 2009;16(3):183-94. Epub 2009/09/08. doi:
1046 10.1016/j.ccr.2009.06.017. PubMed PMID: 19732719; PubMed Central PMCID:
1047 PMC2754404.

- 1048 51. Pillay J, Tak T, Kamp VM, Koenderman L. Immune suppression by
1049 neutrophils and granulocytic myeloid-derived suppressor cells: similarities and
1050 differences. Cellular and molecular life sciences : CMLS. 2013;70(20):3813-27.
1051 Epub 2013/02/21. doi: 10.1007/s00018-013-1286-4. PubMed PMID: 23423530;
1052 PubMed Central PMCID: PMC3781313.
- 1053 52. De Santo C, Arscott R, Booth S, Karydis I, Jones M, Asher R, et al.
1054 Invariant NKT cells modulate the suppressive activity of IL-10-secreting
1055 neutrophils differentiated with serum amyloid A. Nature immunology.
1056 2010;11(11):1039-46. Epub 2010/10/05. doi: 10.1038/ni.1942. PubMed PMID:
1057 20890286; PubMed Central PMCID: PMC3001335.
- 1058 53. Kamp VM, Pillay J, Lammers JW, Pickkers P, Ulfman LH, Koenderman L.
1059 Human suppressive neutrophils CD16bright/CD62Ldim exhibit decreased
1060 adhesion. J Leukoc Biol. 2012;92(5):1011-20. Epub 2012/08/29. doi:
1061 10.1189/jlb.0612273. PubMed PMID: 22927481.
- 1062 54. Pillay J, Kamp VM, van Hoffen E, Visser T, Tak T, Lammers JW, et al. A
1063 subset of neutrophils in human systemic inflammation inhibits T cell responses
1064 through Mac-1. The Journal of clinical investigation. 2012;122(1):327-36. Epub
1065 2011/12/14. doi: 10.1172/JCI57990. PubMed PMID: 22156198; PubMed Central
1066 PMCID: PMC3248287.
- 1067 55. Huynh JP, Lin CC, Kimmey JM, Jarjour NN, Schwarzkopf EA, Bradstreet
1068 TR, et al. Bhlhe40 is an essential repressor of IL-10 during Mycobacterium
1069 tuberculosis infection. The Journal of experimental medicine. 2018;215(7):1823-

- 1070 38. Epub 2018/05/19. doi: 10.1084/jem.20171704. PubMed PMID: 29773644;
1071 PubMed Central PMCID: PMC6028511.
- 1072 56. Tamassia N, Zimmermann M, Castellucci M, Ostuni R, Bruderek K,
1073 Schilling B, et al. Cutting edge: An inactive chromatin configuration at the IL-10
1074 locus in human neutrophils. J Immunol. 2013;190(5):1921-5. Epub 2013/01/29.
1075 doi: 10.4049/jimmunol.1203022. PubMed PMID: 23355741.
- 1076 57. Salmon JE, Cronstein BN. Fc gamma receptor-mediated functions in
1077 neutrophils are modulated by adenosine receptor occupancy. A1 receptors are
1078 stimulatory and A2 receptors are inhibitory. J Immunol. 1990;145(7):2235-40.
1079 Epub 1990/10/01. PubMed PMID: 2168919.
- 1080 58. Barbuti G, Moschioni M, Fumarulo R, Censini S, Montemurro P.
1081 Streptococcus pneumoniae modulates the respiratory burst response in human
1082 neutrophils. FEMS immunology and medical microbiology. 2010;60(1):57-62.
1083 Epub 2010/07/14. doi: 10.1111/j.1574-695X.2010.00716.x. PubMed PMID:
1084 20618848.
- 1085 59. Yesilkaya H, Andisi VF, Andrew PW, Bijlsma JJ. Streptococcus
1086 pneumoniae and reactive oxygen species: an unusual approach to living with
1087 radicals. Trends in microbiology. 2013;21(4):187-95. Epub 2013/02/19. doi:
1088 10.1016/j.tim.2013.01.004. PubMed PMID: 23415028.
- 1089 60. Pericone CD, Park S, Imlay JA, Weiser JN. Factors contributing to
1090 hydrogen peroxide resistance in Streptococcus pneumoniae include pyruvate
1091 oxidase (SpxB) and avoidance of the toxic effects of the fenton reaction. Journal

1092 of bacteriology. 2003;185(23):6815-25. Epub 2003/11/18. PubMed PMID:
1093 14617646; PubMed Central PMCID: PMC262707.

1094 61. Tseng HJ, McEwan AG, Paton JC, Jennings MP. Virulence of
1095 *Streptococcus pneumoniae*: PsaA mutants are hypersensitive to oxidative stress.
1096 *Infect Immun*. 2002;70(3):1635-9. Epub 2002/02/21. PubMed PMID: 11854257;
1097 PubMed Central PMCID: PMC127802.

1098 62. Eijkelkamp BA, Morey JR, Ween MP, Ong CL, McEwan AG, Paton JC, et
1099 al. Extracellular zinc competitively inhibits manganese uptake and compromises
1100 oxidative stress management in *Streptococcus pneumoniae*. *PloS one*.
1101 2014;9(2):e89427. Epub 2014/02/22. doi: 10.1371/journal.pone.0089427.
1102 PubMed PMID: 24558498; PubMed Central PMCID: PMC3928430.

1103 63. van Opijnen T, Camilli A. A fine scale phenotype-genotype virulence map
1104 of a bacterial pathogen. *Genome research*. 2012;22(12):2541-51. Epub
1105 2012/07/25. doi: 10.1101/gr.137430.112. PubMed PMID: 22826510; PubMed
1106 Central PMCID: PMC3514683.

1107 64. Zeng MY, Miralda I, Armstrong CL, Uriarte SM, Bagaitkar J. The roles of
1108 NADPH oxidase in modulating neutrophil effector responses. *Molecular oral
1109 microbiology*. 2019;34(2):27-38. Epub 2019/01/12. doi: 10.1111/omi.12252.
1110 PubMed PMID: 30632295.

1111 65. Nathan C, Cunningham-Bussel A. Beyond oxidative stress: an
1112 immunologist's guide to reactive oxygen species. *Nature reviews Immunology*.
1113 2013;13(5):349-61. Epub 2013/04/27. doi: 10.1038/nri3423. PubMed PMID:
1114 23618831; PubMed Central PMCID: PMCPMC4250048.

- 1115 66. N'Guessan PD, Hippenstiel S, Etouem MO, Zahlten J, Beermann W,
1116 Lindner D, et al. Streptococcus pneumoniae induced p38 MAPK- and NF-
1117 kappaB-dependent COX-2 expression in human lung epithelium. American
1118 journal of physiology Lung cellular and molecular physiology. 2006;290(6):L1131-
1119 8. Epub 2006/01/18. doi: 10.1152/ajplung.00383.2005. PubMed PMID:
1120 16414978.
- 1121 67. Toniolo A, Buccellati C, Pinna C, Gaion RM, Sala A, Bolego C.
1122 Cyclooxygenase-1 and prostacyclin production by endothelial cells in the
1123 presence of mild oxidative stress. PloS one. 2013;8(2):e56683. Epub
1124 2013/02/27. doi: 10.1371/journal.pone.0056683. PubMed PMID: 23441213;
1125 PubMed Central PMCID: PMC3575487.
- 1126 68. Maloney CG, Kutchera WA, Albertine KH, McIntyre TM, Prescott SM,
1127 Zimmerman GA. Inflammatory agonists induce cyclooxygenase type 2
1128 expression by human neutrophils. J Immunol. 1998;160(3):1402-10. Epub
1129 1998/05/07. PubMed PMID: 9570560.
- 1130 69. Nichols RC, Vanderhoek JY. Calcium regulation of the human PMN
1131 cytosolic 15-lipoxygenase. Biochimica et biophysica acta. 1991;1085(1):77-81.
1132 Epub 1991/08/20. doi: 10.1016/0005-2760(91)90234-9. PubMed PMID: 1892881.
- 1133 70. Aeffer F, Woods PS, Davis IC. Activation of A1-adenosine receptors
1134 promotes leukocyte recruitment to the lung and attenuates acute lung injury in
1135 mice infected with influenza A/WSN/33 (H1N1) virus. Journal of virology.
1136 2014;88(17):10214-27. Epub 2014/06/27. doi: 10.1128/JVI.01068-14. PubMed
1137 PMID: 24965449; PubMed Central PMCID: PMC4136329.

71. Aeffer F, Woods PS, Davis IC. Ecto-5'-nucleotidase CD73 modulates the innate immune response to influenza infection but is not required for development of influenza-induced acute lung injury. American journal of physiology Lung cellular and molecular physiology. 2015;309(11):L1313-22. Epub 2015/10/04. doi: 10.1152/ajplung.00130.2015. PubMed PMID: 26432867; PubMed Central PMCID: PMC4669338.
72. Barletta KE, Cagnina RE, Burdick MD, Linden J, Mehrad B. Adenosine A(2B) receptor deficiency promotes host defenses against gram-negative bacterial pneumonia. American journal of respiratory and critical care medicine. 2012;186(10):1044-50. Epub 2012/09/22. doi: 10.1164/rccm.201204-0622OC. PubMed PMID: 22997203; PubMed Central PMCID: PMC3530209.

Figure Legends

Figure 1. Expression of CD73 on pulmonary PMNs changes over the course of infection. C57BL/6 mice were inoculated i.t with 5×10^5 CFU of *S. pneumoniae* TIGR4. The blood, bone marrow and lungs were harvested, plated for bacterial enumeration and analyzed by flow cytometry. (A) Mice were euthanized at 0, 6, 12, 18, 24 and 48 hours following infection. We then compared bacterial numbers in the lungs to PMN numbers (Ly6G+ cells) for the first 0-12 and subsequent 18-72 hours post infection and performed Pearson correlation analysis where asterisks denote significant correlation. We gated on PMNs (Ly6G+ cells) and also monitored (B) the percentage of cells expressing CD73 and (B-C) the amounts of CD73 (mean fluorescent intensity or MFI) in the indicated organs, at

the indicated time points. (D) We gated on all Ly6G⁺ cells and then gated on CD73 positive versus negative populations and compared the expression (MFI) of Ly6G. Data are pooled from two separate experiments with 4-5 mice per time point (A) and 4-7 mice per time point (B-D). Asterisks indicate significant differences from uninfected controls calculated by Student's t-test.

Figure 2. CD73 and extracellular adenosine are required for the ability of neutrophils to kill *S. pneumoniae*. (A) PMNs were isolated from the bone marrow of C57BL/6 (WT) or CD73^{-/-} mice and treated with 100μM Adenosine or PBS (vehicle control) for 30 minutes at 37°C. (B) PMNs were isolated from the bone marrow of C57BL/6 (WT) mice and treated with 100μM of the CD37 inhibitor (α,β methylene ADP), 100μM of the CD39 inhibitor (POM-1) or PBS (vehicle control-VC) for 30 minutes at 37°C. The reactions were then infected with *S. pneumoniae* pre-opsonized with homologous sera for 45 minutes at 37°C. Reactions were then stopped by placing samples on ice and viable CFU were determined after serial dilution and plating. The percentage of bacteria killed upon incubation with PMNs was determined by comparing surviving CFU to a no PMN control. Positive percent killing indicates bacterial death while negative percent indicates bacterial growth. Data shown are pooled from three separate experiments (n=3 biological replicates or mice per strain) where each condition was tested in triplicate (n=3 technical replicates) per experiment. Asterisks indicate significance calculated by Student's t-test. (C) PMNs were isolated from the blood of young healthy donors and pre-treated with the CD73 inhibitor (α,β

methylene ADP) or vehicle control for 30 minutes at 37°C and then incubated for 45 minutes with complement-opsonized *S. pneumoniae* TIGR4. For each donor, the average percent bacterial killing compared to a no PMN control was calculated from triplicate wells per condition. Data from 7 donors are shown. Significant differences denoted by asterisk, were determined by paired t-test.

Figure 3. Adoptive transfer of PMNs from wild type mice boosts resistance

of CD73^{-/-} mice to *S. pneumoniae*. C57BL/6 (WT) or CD73^{-/-} mice were mock treated (no transfer) or injected i.p with 2.5x10⁶ of the indicated PMNs isolated from the bone marrow of C57BL/6 or CD73^{-/-} mice. One hour post transfer, mice were infected i.t with 5x10⁵ CFU of *S. pneumoniae* and bacterial numbers in the lung (A), blood (B) and brain (C) were determined 24 hours post infection. Significant differences, determined by Student's t-test, are indicated by asterisks. Pooled data from n=5 mice per group are shown.

Figure 4. CD73 inhibits IL-10 production from PMNs following

pneumococcal infection. (A) PMNs from the indicated mouse strains were incubated for 45 minutes at 37°C with *S. pneumoniae* pre-opsonized with homologous sera or mock treated with buffer and homologous sera (uninfected) *in vitro*. The supernatants were then collected and assayed for IL-10 production by ELISA. (B) PBS control or adenosine (100μM) were added to the PMNs 30 minutes prior to *in vitro* infection and the fold-change in IL-10 production was calculated by dividing the values of infected reactions by uninfected controls for

each condition. Data were pooled from three separate experiments (n=3 mice) with each condition tested in triplicate per experiment. Asterisks indicate significant differences determined by Student's t-test. (C-E) Wild-type C57BL/6 or CD73^{-/-} mice were mock-infected or i.t challenged with 5 x 10⁵ CFU of *S. pneumoniae*. Six (grey bars) and 18 hours (black bars) following challenge, (C) the percentage of IL-10 producing PMNs (Ly6G+), (D) the mean florescent intensities (MFI) of IL-10 in PMNs (Ly6G+) and (E) the number of IL-10 producing PMNs (Ly6G+) recruited into the lungs were determined by intracellular cytokine staining and flow cytometry (see Materials and Methods). Pooled data are from three separate experiments (n=6-9 mice per strain per time point). Significant differences determined by Student's t-test are indicated by asterisks.

Figure 5. Blocking IL-10 rescues the anti-microbial function of CD73^{-/-} PMNs and reverses the susceptibility of CD73^{-/-} mice to pneumococcal challenge.

(A-B) Wild-type (WT) C57BL/6 or CD73^{-/-} mice were treated i.p with IL-10 blocking antibody JES5-2A5 (anti-IL-10) or isotype control two hours prior to pulmonary challenge with 5x10⁵ CFU of *S. pneumoniae*. Pneumococcal burdens in the lungs (A) and blood (B) were determined 48 hours post-infection. Pooled data from three separate experiments with (CD73^{-/-} +/- anti-IL-10 n=8 mice; WT+ anti-IL-10 n=5 mice and WT + isotype n=13 mice per group) are shown. Values significantly different by Student's t-test are indicated by asterisk. (C) PMNs from C57BL/6 or CD73^{-/-} mice were incubated for 20 minutes with the indicated anti-IL-10 (1µg/ml JES5-2A5), isotype control (1µg/ml), rIL-10 (50ng/ml) or adenosine

(100 μ M) and then infected with pre-opsonized *S. pneumoniae* for 45 minutes at 37°C. Reactions were then plated on blood agar plates and the percentage of bacteria killed compared to a no PMN control under the same conditions was calculated. Data shown are pooled from three separate experiments (n=3 mice per strain) with each condition tested in triplicate. Asterisks indicate significant differences determined by Student's t-test.

Figure 6. Inhibition of IL-10 production by CD73 is important for optimal production of reactive oxygen species by PMNs in response to *S.*

***pneumoniae* infection.** PMN were isolated from the bone marrow of the indicated strains of mice and left untreated (A and B) or treated for 30 minutes with the indicated rIL-10 (50ng/ml) (C) or 100 μ M Adenosine or anti-IL-10 (1 μ g/ml JES5-2A5) or isotype control (1 μ g/ml) (D). PMNs were then infected with *S. pneumoniae* pre-opsonized with homologous sera (+Sp) or treated with 3% matching sera (uninfected) and intracellular ROS production measured by chemiluminescence of Luminol (A) or extracellular ROS production measured by chemiluminescence of Isoluminol in the presence of HRP (B-D). Representative data are shown from one of six (B) and one of four (A, C-D) separate experiments with one mouse per strain per experiment where each condition is tested in quadruplicates. Significant differences ($p<0.05$) were determined by 2-way ANOVA followed by Sidak's multiple comparisons test.

Figure 7. Detoxification of ROS is important for *S. pneumoniae* to resist killing by wildtype, but not CD73^{-/-} PMNs. (A) PMNs isolated from the bone marrow of C57BL/6 (WT) mice were treated with PBS (VC), 10μM DPI, EUK 134 (25μM) or Ascorbic acid (100μM) for 30 minutes at 37°C. (B) PMNs isolated from the bone marrow of C57BL/6 (WT) or CD73^{-/-} mice were left unmanipulated. (C) PMNs isolated from the bone marrow of CD73^{-/-} mice were treated with 100μM adenosine in the absence or presence of EUK 134 or Ascorbic acid for 30 minutes at 37°C. (A-C) The PMNs were then infected with the indicated wild type or Δ sodA *S. pneumoniae* in the presence of homologous sera for 45 minutes at 37°C. Reactions were then stopped by placing samples on ice and viable CFU were determined after serial dilution and plating. The percentage of bacteria killed by comparing surviving CFU to a no PMN control under the same conditions. Data shown are pooled from four separate experiments (n=4 biological replicates or mice per strain) where each condition was tested in triplicate (n=3 technical replicates) per experiment. Asterisks indicate significance calculated by Student's t-test.

Primer Name	Sequence (5' to 3')
SP_0766_F1	GGT CAA AAA CTC AGC GGC AGG AA
SP_0766_R1	CAA CTA TCA TTA CAT CTG TAA TAC CTC TTT TTC
SP_0766_F2	TTA CAG ATG TAA TGA TAG TTG GAG GGA AG
SP_0766_R2	GCG TAC ACT CGA TTC CAA GAC TCA C
SP_0766_ColonyPCRF	GCG ATT TGG TGA GAG ACT TG
SP_0766_ColonyPCRR	CAA ATG ATG CTC GCT TAG GG
OS38	GGAGAACTTAAATGAATTGTAGAGGACATG
OS39	CTATGTGTTTCAGCTGACTCCCATG

Table I. Primers used for generation of Δ sodA *S. pneumoniae*

Figure 1**A.** **B.** **C.** **D.**

Figure 2

Figure 3

A.

B.

C.

Figure 4

Figure 5

Figure 6

Figure 7

Figure S1. Detection of transferred PMNs in the circulation. CD73^{-/-} mice were adoptively transferred 1×10^6 PMNs isolated from bone marrows of wildtype (WT) mice and 1×10^6 PMNs isolated from CD73^{-/-} controls. The transferred PMNs were pre-labeled with CellTracker dyes Orange and Green for WT and CD73^{-/-} respectively and their presence in blood confirmed by flow cytometry 3 hours post transfer. (A) A representative dot plot from one of four recipient mice and (B) the number of the transferred cells per recipient in the blood are shown.

Figure S2. Extracellular adenosine has no direct effect on bacterial survival. (A) The adenosine levels in the sera of mice following pulmonary challenge with 5×10^5 CFU of *S. pneumoniae* were measured using a fluorometric adenosine assay kit. Data shown are pooled from $n=4$ uninfected mice and $n=7$ infected mice. (B) *S. pneumoniae* were incubated with sera only from C57BL/6 (WT) or CD73^{-/-} mice for 40 minutes at 37°C. (C) The indicated concentrations of adenosine or PBS (0) were added prior to the start of incubation. Viable bacteria were enumerated by plating on blood agar plates. (B-C) Data shown represent the means $\pm$ SD and are pooled from two separate experiments with $n=2$ mice and where each condition was tested in triplicates per experiment.

Figure S3. Gating Strategy of IL-10 producing PMNs *in vivo*. Wild-type C57BL/6 or CD73^{-/-} mice were mock-infected or i.t challenged with 5×10^5 CFU of *S. pneumoniae*. Six hours following challenge, the lungs were harvested, incubated with GolgiPlug and stained with Ly6G, IL-10 antibody or isotype control and IL-10 production by PMNs (Ly6G+) and analyzed by flow cytometry. Representative dot plots from one of three separate experiments are shown.

Figure S4. CD73 does not affect bacterial uptake or intracellular killing by PMNs. (A) Bone marrow PMNs from C57BL/6 mice were incubated for 40 minutes at 37°C with wild type or Δ PLY *S. pneumoniae* that were pre-opsonized with homologous sera at an MOI of 2. Gentamicin (50 μ g/ml) was then added for 30 minutes to kill extracellular bacteria. PMNs were washed and plated on blood agar plates to determine the amount of bacteria engulfed and the % of bacteria taken up (uptake) of the original infecting inoculum was calculated. (B) Wild type (*S.p.*) or pneumolysin deficient (Δ PLY *S.p.*) *S. pneumoniae* were incubated with 100 μ g/ml Gentamycin for 30 minutes and the percentage of bacteria killed compared to a mock treatment control was then calculated by plating on blood agar plates. (C) C57BL/6 PMNs were incubated for 45 minutes at 37°C with the indicated strains of wild type (*S.p.*) or pneumolysin deficient (Δ PLY *S.p.*) *S. pneumoniae* pre-opsonized with sera. The percentage of bacteria killed compared to a no PMN control under the same conditions was then calculated by plating for viable bacteria on blood agar plates. (D-E) Bone marrow PMNs from the indicated strains of mice were incubated with *S. pneumoniae* Δ PLY pre-opsonized with homologous sera at an MOI of 2 for 10 minutes at 37°C and gentamicin (50 μ g/ml) was then added for 30 minutes to kill extracellular bacteria. PMNs were then washed and one set (D) immediately plated on blood agar plates to determine the amount of bacteria engulfed and the % of bacteria taken up (uptake) of the original infecting inoculum was calculated. The other sets of PMNs (E) were incubated for 30 and 90 more minutes and then plated to enumerate viable bacteria. The % of bacteria of the engulfed inoculum that was killed was then calculated (Intracellular Killing). Data shown are pooled from (A) two separate experiments, (B) two separate experiments and (C) four separate experiments (n=4 mice) and (D-E) two separate experiments (n=2 mice per strain) where each condition was tested in quadruplicates per experiment. Values significantly different by Student's t-test are indicated by asterisk.

A. **B.** **C.**

Figure S5. CD73 does not affect production of Neutrophil Elastase or myeloperoxidase. (A) PMNs were incubated for 45 minutes at 37°C with pre-opsonized *S. pneumoniae* or mock treated (uninfected) in the presence of control or adenosine (100μM), anti-IL-10 (1μg/ml JES5-2A5) or rIL-10 (50ng/mL). The supernatants were then collected and assayed for (A) Neutrophil Elastase activity (NE) and (B) myeloperoxidase (MPO) levels. (C) The cells were lysed and assayed for MPO levels. Data were pooled from four separate experiments with 4 mice per strain per condition. Asterisk indicated values significantly different from uninfected controls within the same condition by Student's t-test ($p < 0.05$).

A.

Figure S6. CD73/IL-10 do not impact viability. (A) PMNs were mock treated with PBS or treated for 20 minutes with the indicated anti-IL-10 (1 μ g/ml JES5-2A5) or rIL-10 (50ng/ml). PMNs were then incubated for 15 minutes at 37°C with *S. pneumoniae* pre-opsonized with matching sera at an MOI of 2 or mock treated (uninfected) with 3% matching mouse sera only. The percentage of apoptotic cells were then determined by flow cytometry. The percentage of PMNs (gated on Ly6G+ cells) that were double positive for PI and Annexin V are shown. Data were pooled from four separate experiments with 4 mice per strain per condition. Asterisk indicated values significantly different from uninfected controls within the same condition by Student's t-test ($p < 0.05$).